Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Icecure Medical ( (ICCM) ) is now available.
On August 20, 2025, IceCure Medical Ltd. held its Annual and Special General Meeting of Shareholders, where all agenda items were approved by the required majority. This approval signifies strong shareholder support for the company’s strategic direction and could impact its future operations and market positioning.
The most recent analyst rating on (ICCM) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
Spark’s Take on ICCM Stock
According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.
Icecure Medical’s overall stock score is primarily impacted by significant financial challenges, including declining revenues and substantial losses. While there is optimism regarding regulatory progress and clinical achievements, these are overshadowed by ongoing financial difficulties and bearish technical indicators.
To see Spark’s full report on ICCM stock, click here.
More about Icecure Medical
IceCure Medical Ltd. operates in the medical technology industry, focusing on the development and commercialization of minimally invasive cryoablation therapies for the treatment of tumors. The company’s primary product is the ProSense system, which is used for the treatment of breast, kidney, lung, and bone cancers.
Average Trading Volume: 1,119,769
Technical Sentiment Signal: Sell
Current Market Cap: $61.29M
Find detailed analytics on ICCM stock on TipRanks’ Stock Analysis page.